Evidence map›Paper›PMID 42343292›Full record

ArticleBMC cancer2026

Integrated analysis of IGHV rearrangements and cytogenetic abnormalities in a large chronic lymphocytic leukemia cohort (CLL-POL1).

Paulina Własiuk, Monika Szelest, Magdalena Paziewska, Agnieszka Karczmarczyk, Sylwia Czekalska, Magdalena Zawada, Malwina Hut, Oskar Przybyszewski, Michał Soin, Marzena Wojtaszewska and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Paulina Własiuk *Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Monika Szelest *Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland. m.wlodarczyk214@gmail.com.
Magdalena PaziewskaDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Agnieszka KarczmarczykDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.
Sylwia CzekalskaDepartment of Hematological Diagnostics and Genetics, The University Hospital in Krakow, Krakow, Poland.
Magdalena ZawadaDepartment of Hematological Diagnostics and Genetics, The University Hospital in Krakow, Krakow, Poland.
Malwina HutMolecular Diagnostic Laboratory, Department of Laboratory Diagnostics, Copernicus Memorial Hospital, Lodz, Poland.
Oskar PrzybyszewskiMolecular Diagnostic Laboratory, Department of Laboratory Diagnostics, Copernicus Memorial Hospital, Lodz, Poland.
Michał SoinMolecular Diagnostic Laboratory, Department of Laboratory Diagnostics, Copernicus Memorial Hospital, Lodz, Poland.
Marzena WojtaszewskaDepartment of Hematology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.
Monika PępekDepartment of Hematology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.
Agnieszka KwakDiagnostyka Oncogene, Krakow, Poland.
Małgorzata PokrywkaDiagnostyka Oncogene, Krakow, Poland.
Piotr WójcikDiagnostyka Oncogene, Krakow, Poland.
Aleksandra LeszczyńskaDepartment of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
Justyna BukowiczLaboratory of Hematology, University Clinical Centre, Gdansk, Poland.
Wiktoria SzycaLaboratory of Hematology, University Clinical Centre, Gdansk, Poland.
Ewelina Nowak-OzimekDepartment of Molecular Diagnostics, Holy Cross Cancer Centre, Kielce, Poland.
Artur KowalikDepartment of Molecular Diagnostics, Holy Cross Cancer Centre, Kielce, Poland.
Katarzyna BorgClinical Genetics Laboratory, Department of Hematological Diagnostics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Hanna Makuch-ŁasicaClinical Genetics Laboratory, Department of Hematological Diagnostics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Magdalena WojtasClinical Genetics Laboratory, Department of Hematological Diagnostics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Iwona SolarskaMolecular Diagnostic Laboratory, Department of Laboratory Diagnostics, Copernicus Memorial Hospital, Lodz, Poland.
Emilia JaskułaLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Anna Sobczyńska-KonefałLudwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Klaudia ParuzelLaboratory of Cytogenetics, Department of Laboratory Diagnostics, Provincial Specialist Hospital in Biala Podlaska, Biala Podlaska, Poland.
Agnieszka ChudyLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
Ewa WawrzyniakDepartment of Hematology, Medical University of Lodz, Lodz, Poland.
Tomasz StokłosaLaboratory of Genetics, University Clinical Centre of Medical University of Warsaw, Warsaw, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The somatic hypermutation (SHM) status of immunoglobulin heavy-chain variable region gene (IGHV) is a well-established prognostic factor in chronic lymphocytic leukemia (CLL). We analyzed clonotypic IGHV-IGHD-IGHJ rearrangements in 4,251 newly diagnosed CLL patients in Poland (CLL-POL1), representing the largest national cohort to date. In total, 4,328 productive rearrangements were evaluated, of which 93% represented single clonal rearrangements. Additionally, double productive clonal rearrangements were identified in 76 cases (1.8%), of which 27 (35.5%) displayed discordant IGHV SHM status. Stereotyped B-cell receptor subsets were assigned to 10.6% of sequences, predominantly enriched in unmutated CLL (U-CLL) compared to mutated CLL (M-CLL) (72.8% vs. 22%; p < 0.001). High-risk subsets (#1, #2, #5, #6, #59, #99) accounted for over a half of all stereotyped cases and were enriched in patients with TP53 mutation. Most stereotyped subsets showed preferential or exclusive usage of specific IGHV genes. Integration of cytogenetic data revealed a strong enrichment of del(17p), del(11q), and trisomy 12 within U-CLL, whereas M-CLL was characterized by higher frequency of isolated del(13q). In summary, this study highlights distinct IGHV-IGHD-IGHJ pairing preferences and the heterogenous distribution of stereotyped subsets, revealing biologically meaningful associations with TP53 mutation and cytogenetic profiles.

Indexed as

Chromosome AberrationsImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellAdultAgedAged, 80 and overCohort StudiesFemaleHumansMaleMiddle AgedMutationPolandPrognosisSomatic Hypermutation, ImmunoglobulinImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionCLLDiagnosisIGHV

Identifiers

PMID42343292
PMCPMC13551863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.